You just read:

Daiichi Sankyo and ArQule Announce Continuation of METIV-HCC Phase 3 Study of Tivantinib in Second-Line Hepatocellular Carcinoma

News provided by

Daiichi Sankyo

22 Mar, 2016, 11:30 GMT